Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Adagrasib |
| Synonyms | |
| Therapy Description |
Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy, and in combination with Erbitux (cetuximab) for patients with advanced or metastatic colorectal cancer harboring KRAS G12C (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Adagrasib | Krazati | MRTX849|MRTX-849|MRTX 849 | KRAS G12C inhibitor 33 | Krazati (adagrasib) covalently binds to and stabilizes GDP-bound KRAS G12C, thereby preventing KRAS downstream signaling and potentially inhibiting tumor growth (PMID: 31658955). Krazati (adagrasib) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy, and in combination with Erbitux (cetuximab) for patients with advanced or metastatic colorectal cancer harboring KRAS G12C (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03785249 | Phase Ib/II | Adagrasib Adagrasib + Afatinib Adagrasib + Cetuximab Adagrasib + Pembrolizumab | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Recruiting | USA | 1 |
| NCT06248606 | Phase II | Adagrasib | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | Recruiting | USA | 0 |
| NCT05673187 | Phase II | Adagrasib | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT) | Recruiting | ITA | GBR | FRA | ESP | BEL | 1 |
| NCT05472623 | Phase II | Adagrasib + Nivolumab Adagrasib | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab (Neo-Kan) | Recruiting | USA | 0 |
| NCT04613596 | Phase II | Adagrasib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib Carboplatin + Pembrolizumab + Pemetrexed Disodium | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
| NCT05634525 | Phase I | Adagrasib | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | Recruiting | USA | 0 |
| NCT04685135 | Phase III | Docetaxel Adagrasib | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 13 |
| NCT05853575 | Phase II | Adagrasib | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Recruiting | USA | NLD | ITA | FRA | ESP | 12 |
| NCT05162443 | Expanded access | Adagrasib | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | Approved for marketing | USA | 0 |
CKB BOOST